New drug aims to keep myeloma in check after CAR-T

NCT ID NCT06138275

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after treatment with idecabtagene vicleucel (a CAR-T cell therapy). The study will enroll 32 adults with relapsed or refractory multiple myeloma. Participants will receive elranatamab as a shot under the skin to see if it improves response rates and delays disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elranatamab (a drug given as an injection under the skin)
What this could lead to: If it works, this could offer a way to keep multiple myeloma from coming back longer after CAR-T therapy.
What could go wrong: This is a small, early-phase study (32 people) with no control group, so results may not apply broadly. Side effects from elranatamab are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA RELAPSE MULTIPLE MYELOMA

Contacts and locations

Locations

Beth-Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.